AgomAb Therapeutics NV (AGMB) Stock

Healthcare · Biotechnology · Member of Other US Stocks

AgomAb Therapeutics NV (AGMB) closed at USD 8.69 on 2026-10-14, a change of -40.7 % over the past year, with a market capitalization of USD 410.24M.

AgomAb Therapeutics NV recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

AgomAb Therapeutics NV key figures

Previous close

USD 8.69 (2026-10-14)

1-year change

-40.7 %

Market cap

USD 410.24M

Enterprise value

USD 261.67M

P/E ratio (trailing)

-4.21

P/E ratio (forward)

-4.07

EPS (trailing)

-1.98

EPS (forward)

-2.05

PEG ratio

n/a

Price to book

3.28

Revenue growth

n/a

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

6.13

Employees

62

Analyst consensus (third-party)

strong_buy

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About AgomAb Therapeutics NV

AgomAb Therapeutics NV, a clinical-stage biopharmaceutical company, develops novel disease-modifying therapies for immunology and inflammatory diseases in the United States. The company's product pipeline includes Ontunisertib (AGMB-129), an oral gastrointestinal-restricted small molecule inhibitor of ALK5 or TGFßR1 for the treatment of Fibrostenosing Crohn's disease, which is in Phase 2a clinical trials; and AGMB-447, an inhaled small molecule inhibitor of ALK5 or TGFßR1 for the treatment of idiopathic pulmonary fibrosis that is in Phase 1 clinical trials. It also develops AGMB-101, a HGF-mimetic monoclonal antibody that acts through agonism or stimulation of the MET receptor and has demonstrated antifibrotic and regenerative activity in preclinical models. The company was incorporated in 2017 and is headquartered in Antwerp, Belgium.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for AgomAb Therapeutics NV and compare it with other stocks.